Sanofi SA (NASDAQ:SNY) on Wednesday announced that it will discontinue its Phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who had not responded to standard treatments.

CIDP is a rare, acquired autoimmune disorder of the peripheral nervous system in which the body’s immune system attacks the myelin sheaths around nerve cells in the peripheral nervous system.

The decision followed an assessment by an independent data monitoring committee, which determined that the study was not expected to meet its efficacy objectives.

Sanofi said the review did not identify any safety concerns related to riliprubart.

Read Also:

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

Sanofi To Review Broader Riliprubart Development Program

The company said it will assess the future of other ongoing riliprubart studies, including the Phase 3 VITALIZE trial involving ...